Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.

< BACK TO ARCHIVE


2020 Feb 01


Rhinology


http://www.ncbi.nlm.nih.gov/pubmed/31671432?dopt=Abstract


58


1

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.

Authors

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C, Zinreich JS, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Amin N, Joish VN, Fan C, Zhang D, Staudinger H, Pirozzi G, Graham NMH, Khan A, Mannent LP
Rhinology. 2020 Feb 01; 58(1):10-17.
PMID: 31671432.

Abstract

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus opacification. In a phase 2a study (NCT01920893), dupilumab, a fully human anti-IL-4Rα monoclonal antibody, improved outcomes in CRSwNP refractory to intranasal corticosteroids. We evaluated dupilumab's effect on sinus opacification in relation to effects on nasal polyp burden, symptoms, and health-related quality of life (HRQoL) in patients with CRSwNP.
Read This Paper